This demonstrates that IL-1β is a downstream mediator of IL-6 and its regulation is a fundamental part of the signaling mechanisms underlying beneficial effects of IL-6 in non-steatotic grafts subjected to LT and BD. This evidence concerns the gene IL6 and Behcet disease.